查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
RNA治療藥及RNA疫苗市場:各種模式，各分子類型，各治療領域，各給藥途徑，各主要地區，主要加入企業:產業趨勢全球預測，2023年～2035年
市場調查報告書
商品編碼
1347906

RNA治療藥及RNA疫苗市場:各種模式，各分子類型，各治療領域，各給藥途徑，各主要地區，主要加入企業:產業趨勢全球預測，2023年～2035年

RNA Therapeutics Market & RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions & Leading Players: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

下一代RNA疫苗和RNA療法的市場狀況比較集中，大型公司、中型公司和中小企業超過35家。其中 50% 成立於 2016 年至 2020 年期間，顯示該治療市場領域的初創活動很高。此外，超過 70% 的公司總部位於北美。在歐洲，英國正在成為參與下一代 RNA 療法和 RNA 疫苗開發的公司的中心。

目前，超過 100 種下一代 RNA 療法和 RNA 疫苗已獲得批准或正在不同的開發階段進行評估。此外，分別有 40% 和 32% 的候選藥物正處於不同開發階段，用於治療傳染病和腫瘤疾病。這些候選藥物已成為治療開發商中流行的標靶療法。

近年來，隨著醫療保健產業的進步，各種新藥被開發出來。有趣的是，該行業正在評估下一代 RNA 療法和 RNA 疫苗，它們正在成為針對多種適應症的標靶療法。

自 2021 年以來，已註冊 18 項臨床試驗來評估下一代 RNA 療法和疫苗。其中，72% 是針對傳染病的試驗。這可能是由於行業參與者開發針對 COVID-19 的治療方法的活動增加。有趣的是，其中 27% 的臨床試驗已進入開發後期（II 期及以上）。隨著下一代 RNA 療法和 RNA 疫苗進入臨床開發軌道，預計市場在預測期內將以有利的複合年增長率成長。

RNA 疫苗引起了製藥業的關注，特別是在 COVID-19 大流行期間，第一代基於 mRNA 的 COVID 疫苗獲得了監管部門的批准。在 mRNA 疫苗出現之前，其他方法（例如反義 RNA、siRNA 和 RNA 適體）被評估為治療劑。Gemcovac(R) 由 HDT Bio 開發，是第一種基於自擴增 mRNA (saRNA) 的新冠疫苗，於 2022 年 6 月在印度獲得緊急使用授權。這種新冠疫苗目前正在美國、巴西和韓國進行臨床試驗。關鍵臨床試驗結果表明，與 Moderna 和輝瑞開發的新冠疫苗相比，Gemcovac(R) 的不良事件發生率要低得多。這種治療的免疫反應與阿斯特捷利康開發的免疫反應相當。此外，Gemcovac(R) 以凍乾粉末形式提供，因此需要儲存在普通冰箱中。這種自擴增 mRNA 疫苗是皮內注射的，與許多肌肉注射的新冠疫苗不同。由於其高度穩定的結構、改進的治療方案和低濃度給藥，下一代 RNA 療法和 RNA 疫苗正在成為傳統 RNA 方法的潛在替代品。

這場大流行極大地推動了基於 RNA 的療法的發展。從那時起，行業利益相關者一直積極致力於開發持久且能夠針對廣泛治療標靶的療法，並使用各種方法開發下一代 RNA 療法和 RNA 疫苗。

由於人們對研發活動的興趣日益濃厚，以及對罕見腫瘤疾病有效治療的需求不斷增長，下一代 RNA 療法和 RNA 疫苗市場預計將在預測期內（2026-2026 年）增長。預計到2035年，複合年增長率(CAGR) 將超過50%）。具體來說，從分子類型來看，全球下一代 RNA 療法和 RNA 疫苗市場預計將由自我擴增 mRNA 推動。同樣，從治療領域來看，針對癌症和肺部疾病的 RNA 療法和 RNA 疫苗預計將主導市場。

此外，到 2035 年，近 94% 的市佔率將由北美公司佔。然而，值得注意的是，亞太地區下一代RNA療法和RNA疫苗市場預計在預測期（2030-2035年）將以更高的複合年增長率成長。

本報告提供全球RNA治療藥及RNA疫苗市場相關調查，提供市場概要，以及各種模式，各分子類型，各治療領域，各給藥途徑，各主要地區，按主要加入企業趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 調查手法

第3章 經濟以及其他的計劃特有的考慮事項

第4章 摘要整理

第5章 簡介

第6章 市場形勢

  • RNA治療藥及RNA疫苗:治療的大氣候
  • RNA治療藥及RNA疫苗:臨床階段的治療形勢
  • RNA治療藥及RNA疫苗:治療開發商的形勢
  • RNA治療藥及RNA疫苗:循環RNA治療的形勢
  • RNA治療藥及RNA疫苗:自我放大RNA治療的形勢

第7章 技術形勢

  • RNA治療藥及RNA疫苗:下一代RNA技術的形勢
  • RNA治療藥及RNA疫苗:下一代RNA技術/平台開發商的形勢

第8章 藥物簡介

  • gemukovatsu
  • ATYR1923
  • ARCT-154
  • GRT-C901
  • VLPCOV-01
  • AVX901
  • MTL-CEBPA+Sorafenib
  • 石板瓦

第9章 臨床試驗的分析

  • 分析調查手法主要的參數
  • RNA治療藥及RNA疫苗:臨床試驗分析

第10章 專利分析

  • 分析調查手法主要的參數
  • RNA治療藥及RNA疫苗:專利分析
  • RNA治療藥及RNA疫苗:專利基準分析
  • RNA治療藥及RNA疫苗:專利評估分析

第11章 夥伴關係和合作

第12章 資金籌措和投資的分析

第13章 大型製藥公司的配合措施

  • RNA治療藥及RNA疫苗:大型製藥公司的配合措施

第14章 RNA治療藥及RNA疫苗市場全體，2023年年～2035年

第15章 RNA治療藥及RNA疫苗市場全體，各種模式

第16章 RNA治療藥及RNA疫苗市場全體，各分子類型

第17章 RNA治療藥及RNA疫苗市場全體，各治療領域

第18章 RNA治療藥及RNA疫苗市場全體，各給藥途徑

第19章 RNA治療藥及RNA疫苗市場全體，各主要地區

第20章 RNA治療藥及RNA疫苗市場全體，各主要企業

第21章 結論

第22章 附錄1:表格形式的資料

第23章 附錄2:企業及組織的清單

Product Code: RA100454

INTRODUCTION

The global RNA Vaccines and RNA Therapeutics market is estimated to be worth over USD 1.1 billion in 2035 and is expected to grow at compounded annual growth rate (CAGR) of 50% during the forecast period (2026-2035).

In the past few years, RNA based therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches. However, there are some concerns associated with the highly unstable nature of such molecules and their delivery at adequate concentrations. Therefore, in order to address the challenges pertaining to the use of RNA therapeutics and RNA vaccines, several industry players have been engaged in the development / deployment of novel technologies for the design, development and manufacturing of next generation RNA-based therapeutics / vaccines, offering the healthcare sector a promising disease management recourse.

The next generation RNA therapeutics and RNA vaccines are modified treatment molecules aimed at specifically targeting and treating diseases that were earlier considered undruggable. Among these, innovative modalities, such as circular RNA (circRNA), endless RNA (eRNA), self activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA) have emerged as popular targeted therapeutics. The success of these next generation RNA therapeutics and RNA vaccines can be attributed to their structural stability, expression specificity, targeted delivery, non-immunogenic nature, high efficiency and ability to target a wide range of therapeutic modalities, including influenza, COVID-19 infection, breast cancer and interstitial lung disease, among others.

Further, owing to their self-replicating nature, such RNA-based therapies offer prolonged therapeutic effects at relatively low and less frequent doses, as compared to traditional methods.

Given the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation RNA vaccines and RNA therapeutics market is likely to witness significant growth during the forecast period.

SCOPE OF THE REPORT

"The RNA Vaccines and RNA Therapeutics Market: Distribution by Type of Modality (RNA Therapeutics and RNA Vaccines), Type of Molecule (replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA), Therapeutic Areas (Infectious Diseases, Oncological Disorders and Pulmonary Disorders), Route of Administration (Intradermal, Intramuscular and Intravenous), Key Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players: Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape, market size and future opportunities associated with the RNA vaccines and RNA therapeutics market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.

Key takeaways of the RNA vaccines and RNA therapeutics market are briefly discussed below.

Current Market Landscape: Next Generation RNA Therapeutics and RNA Vaccines Offering Efficient Treatment Recourse

The next generation RNA vaccines and RNA therapeutics market landscape is concentrated with the presence of over 35 large, mid-sized and small companies. Of these, 50% of the companies were established during the period 2016-2020, indicating significant start-up activity in this therapeutic market segment. Examples of companies (established in 2019 and 2020, in alphabetical order) include Chimerna Therapeutics, Orna Therapeutics, Replicate Bioscience, Transine Therapeutics, VaxEquity, VLP Therapeutics and Ziphius Vaccines. Further, more than 70% of the companies are based in North America. Within Europe, the UK has emerged as the hub of players engaged in the development of next generation RNA therapeutics and RNA vaccines.

It is worth mentioning that, currently, over 100 next generation RNA therapeutics and RNA vaccines are either approved or being evaluated in various stages of development; of these, nearly 25% of the drug candidates are being evaluated in clinical trials. Further, 40% and 32% of the drug candidates are being investigated for the treatment of infectious diseases and oncological disorders, respectively, across different phases of development. These drug candidates have emerged as popular targeted therapy among therapy developers.

Recent advancements in the healthcare industry in the last few years have led to the development of various novel drug modalities. Interestingly, the industry is evaluating next generation RNA therapeutics and RNA vaccines, which have surfaced as possible targeted therapies for a wide range of therapeutic indications.

Clinical Trials Analysis: A number of RNA Therapeutics and RNA Vaccines are Being Evaluated in Clinical Trials

It is important to highlight that a therapeutic modality, ATYR1923, developed by aTyr Pharma, is currently being investigated in phase III, targeting Pulmonary Sarcoidosis. Recently, in August 2022, the drug received fast track designation from the USFDA. Over 1,160 clinical trial initiatives focused on various next generation drug modalities, such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA), long non coding RNA and others have been undertaken since 2019, indicating the substantial research efforts being made in this industry.

Since 2021, 18 clinical trials have been registered for the evaluation of next generation RNA therapeutics and vaccines. Of these, 72% of the trials were focused on infectious diseases. This can be attributed to the enhanced activity of industry players towards the development of therapies targeting COVID-19. Interestingly, 27% of these trials have advanced to the late stages of development (phase II and above). As the next generation RNA therapeutics and RNA vaccines move along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.

Self Amplifying mRNA Vaccines Offer Several Advantages Over the First Generation mRNA Vaccines

RNA vaccines have caught the attention of the pharmaceutical industry, specifically during the COVID-19 pandemic, when the first generation mRNA based COVID vaccine received approval from regulatory authorities. Prior to mRNA vaccines, other modalities, such as antisense RNA, siRNA and RNA aptamers were evaluated as therapeutics. Gemcovac®, developed by HDT Bio was the first self amplifying mRNA (saRNA) based COVID vaccine to receive emergency use approval in India, in June 2022. Notably, this COVID vaccine is currently being evaluated in clinical trials in the US, Brazil and South Korea. According to the pivotal trial results, Gemcovac® demonstrated a much lower rate of adverse events as compared to the COVID vaccine, developed by Moderna and Pfizer. The immunological response of the therapy was comparable to that developed by AstraZeneca. Additionally, Gemcovac® is supplied in lyophilized powder form and requires storage in a normal refrigerator. This self amplifying mRNA vaccine is delivered intradermally, unlike most of the COVID vaccines that are administered intramuscularly. Owing to their highly stable structure, enhanced therapeutic profile and low concentration administration, the next generation RNA therapeutics and RNA vaccines have emerged as a potential alternative to conventional RNA-based approaches.

Another player, Arcturus Therapeutics is developing the COVID vaccine using its proprietary self amplifying mRNA technology platform. In April 2023, its collaboration partner, Meiji Seika Pharma, submitted an NDA to commercialize the vaccine, ARCT-154, in Japan. The launch of more such self amplifying mRNA vaccines will drive the market growth over the forecast period.

Potential of tRNA Therapeutics is Being Explored by Few Key Companies

The pandemic offered a major thrust to RNA-based therapies. Since then, industry stakeholders are actively being engaged in the development of therapies that are long lasting and can target a wide range of therapeutic targets, giving rise to the development of next generation RNA therapeutics and RNA vaccines using various approaches.

One such approach involves the use of transfer RNA (tRNA), being engineered by US-based Alltrna, in order to correct gene code and ultimately gene expression. The company raised USD 50 million in Series A funding in 2020. However, Alltrna is not the sole company working on tRNA technology. Other companies include ReCode Therapeutics, ShapeTX, Tevard Biosciences and hC Bioscience. The current tRNA market landscape features the presence of close to ten therapies, of which, majority are still in early stages of development. These therapies are primarily being developed to target indications, such as Cystic Fibrosis, Duchenne Muscular Dystrophy and Pulmonary Sarcoidosis.

Circular RNA Therapeutics Market is Witnessing a number of Start Ups and Funding Activity

Circular RNA is a covalently bonded closed-loop RNA structure, engineered from linear RNAs by circularization. These structures confer higher stability to the RNA molecules, protecting the molecule from rapid degradation by exonucleases. Recently, the next generation RNA therapeutics and vaccines domain has witnessed the emergence of industry players engaged in the development of circular RNA therapies, owing to the vast potential and high stability of such therapies. Examples of some players include (in alphabetical order) Chimerna Therapeutics, Esperovax, Flagship Pioneering's Laronde, Ginkgo Bioworks, Orna Therapeutics, Ring Code Biotech, Circio and Therorna. Notably, since 2019, more than USD 380 million has been raised / invested by companies engaged in the development of circular RNA, reflecting significant funding activity for circular RNA-based therapies in this domain.

It is worth highlighting that industry players are actively collaborating with circular RNA therapy developers in order to support the discovery, development and delivery of circRNA molecules. For instance, Renagade Therapeutics has entered into a collaboration with Orna Therapeutics in order to support the delivery of circular RNA therapies being discovered by Orna Therapeutics. Considering the potential of these therapies, several industry stakeholders are actively engaging in the development of such therapeutics. The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and market growth over the forecast period.

Key Trends in the Next Generation RNA Therapeutics and RNA Vaccines Market

Many stakeholders are undertaking initiatives to forge alliances with other industry / non-industry players. Of the strategic partnerships focused on next generation RNA therapeutics and RNA vaccines that have been inked since 2019, close to 22% of partnerships are research and development agreements, indicating that the stakeholders are actively engaged in research and development of these next generation RNA therapeutics and RNA vaccines. Interestingly, it was observed that many big pharma players, such as Merck, Gilead Sciences, AstraZeneca and others have partnered with several next generation RNA therapeutics and RNA vaccines players, in order to expand their respective portfolios. It is worth highlighting that a sum of $2.9 billion has been raised / invested by players engaged in the development of RNA therapeutics and RNA vaccines, indicating the interest of stakeholders in this market.

Given the inclination towards development of novel next generation RNA therapeutics and RNA vaccines, along with the engagement of big pharma players and high investments, we believe that the next generation RNA therapeutics and RNA vaccines market is likely to evolve at a rapid pace over the forecast period.

Next Generation RNA Vaccines and RNA Therapeutics Market Size: North America to Hold the Largest Market Share

Driven by the rising interest in R&D activities and growing demand for effective therapies for rare and oncological disorders, the next generation RNA therapeutics and RNA vaccines market is anticipated to witness an annualized growth rate (CAGR) of over 50%, during the forecast period (2026-2035). Specifically, in terms of type of molecule, the global market for next generation RNA therapeutics and RNA vaccines is anticipated to be driven by self amplifying mRNAs. Likewise, in terms of therapeutic area, the market is anticipated to be dominated by the RNA therapeutics and RNA vaccines targeting oncological disorders and pulmonary disorders.

In addition, close to 94% of the market share in 2035 is captured by the players based in North America. However, it is worth highlighting that the next generation RNA therapeutics and RNA vaccines market in Asia-Pacific is anticipated to grow at a higher CAGR, during the forecast period (2030-2035).

Recently, the increasing number of orphan and fast track designations granted by the regulatory authorities, such as the USFDA and the EMA, has intrigued interest and increased the confidence of the pharmaceutical industry in these novel targeted therapies. All the above factors will contribute to a healthy market growth of the next generation RNA therapeutics and RNA vaccines market during the forecast period.

Leading Next Generation RNA Therapeutics and RNA Vaccines Developers

Examples of key companies engaged in the next generation RNA therapeutics and RNA vaccines development (which have also been captured in this market report, arranged in alphabetical order) include Alphavax, Arcturus Therapeutics, Atyr Pharma, Flagship Pioneering, Forge Therapeutics, Gingko Bioworks, Gritstone Bio, HDT Bio, Laronde Therapeutics, MiNA Therapeutics, Orna Therapeutics, Recode Therapeutics, Renegade Therapeutics, Replicate Bioscience, Shape Therapeutics and VLP Therapeutics. This market report includes an easily searchable excel database of all the companies developing next generation RNA therapeutics and RNA vaccines, worldwide.

Recent Developments in the Next Generation RNA Vaccines and RNA Therapeutics Market

Several recent developments have taken place in the field of next generation RNA vaccines and RNA therapeutics, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we've outlined in our analysis.

  • In February 2023, Tevard Biosciences entered into a research and development agreement with Vertex Pharmaceuticals for the development of novel tRNA based therapies, intended for the treatment of Duchenne Muscular Dystrophy.
  • In January 2023, Esperovax entered into a product development agreement with Gingko Bioworks for the development of circular RNA therapeutics, specifically targeting colorectal cancer.
  • Further, in January 2023, HDT Bio entered into a technology utilization agreement with the Pan African Cancer Research Institute (PACRI), in order to develop self-amplifying RNA vaccines and therapeutics.

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, RNA Therapeutics and RNA Vaccines Market, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on next generation RNA therapeutics and RNA vaccines market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall next generation RNA therapeutics and RNA vaccines market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during our research, offering a high-level view of the current state of the next generation RNA therapeutics and RNA vaccines market and its likely evolution in the mid-to-long term.
  • A brief introduction to the next generation RNA therapeutics and RNA vaccines, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using next generation RNA modalities.
  • A detailed assessment of the market landscape of more than 100 next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), type of delivery vehicle (lipid nanoparticles, viral vectors, non-lipid nanoparticles, non-viral vectors and polymers), phase of development (discovery, preclinical, phase I, phase I / II, phase II, phase II / III, phase III and emergency use approval), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, immunological disorders and other disorders). Further, the chapter features analysis on key niche market segments (circRNA and saRNA). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • A detailed assessment of the market landscape of more than 35 technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as class of molecule (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), capabilities of the technology (development, delivery, research and discovery, design and manufacturing), therapeutic area (oncological disorders, infectious diseases, genetic disorders, neurological disorders, immunological disorders, cardiovascular disorders, inflammatory disorders, ophthalmic disorders, rare disorders, pulmonary disorders, unspecified and other disorders) and highest phase of development (discovery, preclinical, clinical and commercial). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their year of establishment, company size, location of headquarters and operational model.
  • Elaborate profiles of drug candidates that are in advanced stages of development (Phase II, III and above). Each drug profile features details on its developer, drug overview, clinical trial information, clinical trial endpoints, clinical trial results and estimated sales.
  • An in-depth analysis of completed and ongoing clinical trials of various next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, patients enrolled, type of sponsor, therapeutic area, study design, leading organizations (in terms of number of trials), focus area and geography.
  • An in-depth analysis of patents related to next generation RNA therapeutics and RNA vaccines, filed / granted, since 2019, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), patent publication year, patent jurisdiction, CPC symbols, emerging focus areas, patent age, leading industry / non-industry players (in terms of number of patents filed / granted), and patent valuation.
  • An in-depth analysis of partnerships that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, type of molecule, focus of partnership, purpose of partnership, therapeutic area and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
  • A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of molecule, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
  • An in-depth analysis of the various next generation RNA therapeutics and RNA vaccines focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.

One of the key objectives of this market report was to estimate the current market size and the future growth potential of the next generation RNA therapeutics and RNA vaccines over the forecast period. Based on several parameters, such as region-specific adoption rates and expected prices of such modalities, we have developed informed estimates of the likely evolution of the next generation RNA vaccines and RNA therapeutics market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (repRNA, saRNA, sacRNA, samRNA and tRNA), therapeutic area (infectious diseases, oncological disorders and pulmonary disorders), route of administration (intradermal, intramuscular and intravenous), key geographical regions (North America, Europe and Asia-Pacific) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and secondary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this market report has been gathered via secondary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What are RNA-based therapeutics?

Answer: RNA-based molecules are a class of therapeutics that utilize RNA molecules for specifically targeting genes in order to regulate their function and expression. The altered gene expression aids in the management of several disease indications by producing the desired therapeutic effect.

Question 2: What is self replicating RNA mechanism? What are self-amplifying mRNA vaccines?

Answer: The self replicating property of RNA molecules enables them to create multiple copies of themselves within the cell without using additional cellular machinery, such as proteins and DNA. The mechanism involves the use of a short RNA strand as the template guide to synthesize a complementary copy of itself, thereby generating a new RNA molecule. The two new molecules then segregate to act as the template guides for further replication.

Question 3: What are self-amplifying mRNA vaccines?

Answer: Self-amplifying mRNA vaccines utilize a strand of messenger RNA designed to self-replicate and elicit a sustained immune response when administered to the human body. Owing to the self-replicating nature, the vaccine would not require frequent administration and would lead to a higher expression of proteins even at low dose concentration.

Question 4: Are RNA-based therapies approved by the FDA?

Answer: RNA-based therapies are continuously being evaluated in clinical trials for their safety and efficacy in the treatment of a wide range of therapeutic indications. It is worth noting that the first clinical trial of an mRNA-based vaccine was conducted in 2008. However, the first mRNA vaccine received the FDA approval for the treatment of COVID in 2021.

Question 5: What RNA drugs are FDA approved?

Answer: Interestingly, close to 10 RNA therapeutics have been approved till date. Of these, the primary types of therapies include those based on antisense oligonucleotides and small interfering RNA molecules. Further, Gemcovac®, a self amplifying RNA vaccine, has been granted emergency use approval as a COVID vaccine in India.

Question 6: How big is the next generation RNA vaccines and RNA therapeutics market?

Answer: The market size for the next generation RNA therapeutics and RNA vaccines market is estimated to be USD 1.1 billion in 2035.

Question 7: What is the likely market growth rate (CAGR) for the next generation RNA vaccines and RNA therapeutics market?

Answer: The market size for next generation RNA therapeutics and RNA vaccines is projected to grow at an annualized rate (CAGR) of ~50%, during the forecast period (2026-2035).

Question 8: Who are the leading companies in the next generation RNA therapeutics and RNA vaccines market?

Answer: Some of the leading companies engaged in the next generation RNA therapeutics and RNA vaccines development (which have also been captured in this market report, arranged in alphabetical order) include Arcturus Therapeutics, Flagship Pioneering, Forge Therapeutics, Gingko Bioworks, Laronde Therapeutics, Orna Therapeutics, Recode Therapeutics, Renegade Therapeutics, Replicate Bioscience and Shape Therapeutics.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an overview of the full report, RNA Therapeutics and RNA Vaccines Market, 2023-2035.
  • Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on next generation RNA therapeutics and RNA vaccines market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • Chapter 3 is an overview of economic factors that impact the overall next generation RNA therapeutics and RNA vaccines market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • Chapter 4 is an executive summary of the key insights captured during our research, offering a high-level view of the current state of the next generation RNA therapeutics and RNA vaccines market and its likely evolution in the mid-to-long term.
  • Chapter 5 provides a general overview of the next generation RNA therapeutics and RNA vaccines, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using next generation RNA modalities.
  • Chapter 6 provides information on more than 100 next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), type of delivery vehicle (lipid nanoparticles, viral vectors, non-lipid nanoparticles, non-viral vectors and polymers), phase of development (discovery, preclinical, phase I, phase I / II, phase II, phase II / III, phase III and emergency use approval), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, immunological disorders and other disorders). Further, the chapter features analysis on key niche market segments (circRNA and saRNA). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • Chapter 7 provides information on more than 35 technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as class of molecule (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), capabilities of the technology (development, delivery, research and discovery, design and manufacturing), therapeutic area (oncological disorders, infectious diseases, genetic disorders, neurological disorders, immunological disorders, cardiovascular disorders, inflammatory disorders, ophthalmic disorders, rare disorders, pulmonary disorders, unspecified and other disorders) and highest phase of development (discovery, preclinical, clinical and commercial). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their year of establishment, company size, location of headquarters and operational model.
  • Chapter 8 presents elaborate profiles of drug candidates that are in the advanced stages of development (Phase II, III and above). Each drug profile features details on its developer, drug overview, clinical trial information, clinical trial endpoints, clinical trial results and estimated sales.
  • Chapter 9 presents an in-depth analysis of completed and ongoing clinical trials of various next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, patients enrolled, type of sponsor, therapeutic area, study design, leading organizations (in terms of number of trials), focus area and geography.
  • Chapter 10 provides in-depth analysis of patents related to next generation RNA therapeutics and RNA vaccines, filed / granted, since 2019, based on type of patent (granted patents, patent applications and others), patent publication year, patent jurisdiction, CPC symbols, emerging focus areas, patent age, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
  • Chapter 11 presents an in-depth analysis of partnerships that have been inked between various stakeholders since 2019, based on various parameters, such as the year of partnership, type of partnership, type of molecule, focus of partnership, purpose of partnership, therapeutic area and most active players (in terms of number of partnerships). The chapter also highlights the regional distribution of partnership activity in this market.
  • Chapter 12 features an in-depth analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of molecule, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
  • Chapter 13 presents an in-depth analysis of the various next generation RNA therapeutics and RNA vaccines focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
  • Chapter 14 provides a detailed market forecast analysis in order to estimate the existing market size and future opportunity for next generation RNA therapeutics and vaccines, till the year 2035. Based on multiple parameters and likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the RNA therapeutics and RNA vaccines market. Further, in order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.
  • Chapter 15 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different types of modalities, including therapeutics and vaccines.
  • Chapter 16 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different types of molecules, including repRNA, saRNA, sacRNA, samRNA and tRNA.
  • Chapter 17 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different therapeutic areas, including infectious diseases, oncological disorders and pulmonary disorders.
  • Chapter 18 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different routes of administration, including intradermal, intramuscular and intravenous.
  • Chapter 19 detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world.
  • Chapter 20 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across the leading players engaged in this domain.
  • Chapter 21 summarizes the entire report, highlighting various facts related to contemporary market trends and the likely evolution of the RNA therapeutics and RNA vaccines market, based on the research and analysis described in the previous chapters.
  • Chapter 22 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 23 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. RNA Therapeutics and RNA Vaccines Market Overview
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
  • 5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
  • 5.3. Types of Next Generation RNA Molecules
  • 5.4. Key Aspects of Next Generation RNA Molecules
  • 5.5. Key Challenges Associated with Traditional RNA Modalities
  • 5.6. Advantages of Using Next Generation RNA Modalities

6. MARKET LANDSCAPE

  • 6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
    • 6.1.1. Analysis by Type of Modality
    • 6.1.2. Analysis by Type of Molecule
    • 6.1.3. Analysis by Delivery Vehicle
    • 6.1.4. Analysis by Phase of Development
    • 6.1.5. Analysis by Therapeutic Area
    • 6.1.6. Most Active Players: Analysis by Number of Therapies
  • 6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
    • 6.2.1. Analysis by Phase of Development
    • 6.2.2. Analysis by Route of Administration
    • 6.2.3. Analysis by Therapeutic Area
  • 6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
  • 6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
    • 6.4.1. Analysis by Phase of Development
    • 6.4.2. Analysis by Therapeutic Area
    • 6.4.3. Most Active Players: Analysis by Number of Therapies
  • 6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
    • 6.5.1. Analysis by Phase of Development
    • 6.5.2. Analysis by Therapeutic Area
    • 6.5.3. Most Active Players: Analysis by Number of Therapies

7. TECHNOLOGY LANDSCAPE

  • 7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
    • 7.1.1. Analysis by Class of Molecule
    • 7.1.2. Analysis by Type of Molecule
    • 7.1.3. Analysis by Capabilities of the Technology
    • 7.1.4. Analysis by Therapeutic Area
    • 7.1.5. Analysis by Highest Phase of Development
  • 7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Operational Model

8. DRUG PROFILES

  • 8.1. Gemcovac
    • 8.1.1. Developer Overview
    • 8.1.2. Drug Overview
    • 8.1.3. Clinical Trial Information
    • 8.1.4. Clinical Trial Endpoints
    • 8.1.5. Clinical Trial Results
    • 8.1.6. Estimated Sales
  • 8.2. ATYR1923
    • 8.2.1. Developer Overview
    • 8.2.2. Drug Overview
    • 8.2.3. Clinical Trial Information
    • 8.2.4. Clinical Trial Endpoints
    • 8.2.5. Clinical Trial Results
    • 8.2.6. Estimated Sales
  • 8.3. ARCT-154
    • 8.3.1. Developer Overview
    • 8.3.2. Drug Overview
    • 8.3.3. Clinical Trial Information
    • 8.3.4. Clinical Trial Endpoints
    • 8.3.5. Clinical Trial Results
    • 8.3.6. Estimated Sales
  • 8.4. GRT-C901
    • 8.4.1. Developer Overview
    • 8.4.2. Drug Overview
    • 8.4.3. Clinical Trial Information
    • 8.4.4. Clinical Trial Endpoints
    • 8.4.5. Clinical Trial Results
    • 8.4.6. Estimated Sales
  • 8.5. VLPCOV-01
    • 8.5.1. Developer Overview
    • 8.5.2. Drug Overview
    • 8.5.3. Estimated Sales
  • 8.6. AVX901
    • 8.6.1. Developer Overview
    • 8.6.2. Drug Overview
    • 8.6.3. Clinical Trial Information
    • 8.6.4. Clinical Trial Endpoints
    • 8.6.5. Clinical Trial Results
    • 8.6.6. Estimated Sales
  • 8.7. MTL-CEBPA + Sorafenib
    • 8.7.1. Developer Overview
    • 8.7.2. Drug Overview
    • 8.7.3. Clinical Trial Information
    • 8.7.4. Clinical Trial Endpoints
    • 8.7.5. Clinical Trial Results
    • 8.7.6. Estimated Sales
  • 8.8. SLATE
    • 8.8.1. Developer Overview
    • 8.8.2. Drug Overview
    • 8.8.3. Clinical Trial Information
    • 8.8.4. Clinical Trial Endpoints
    • 8.8.5. Clinical Trial Results
    • 8.8.6. Estimated Sales

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Analysis Methodology and Key Parameters
  • 9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
    • 9.2.1. Analysis by Trial Registration Year
    • 9.2.2. Analysis by Trial Status
    • 9.2.3. Analysis by Trial Registration Year and Trial Status
    • 9.2.4. Analysis by Trial Phase
    • 9.2.5. Analysis by Patients Enrolled
    • 9.2.6. Analysis by Type of Sponsor
    • 9.2.7. Analysis by Therapeutic Area
    • 9.2.8. Analysis by Study Design
    • 9.2.9. Leading Organizations: Analysis by Number of Trials
    • 9.2.10. Analysis by Focus Area
    • 9.2.11. Analysis by Geography

10. PATENT ANALYSIS

  • 10.1. Analysis Methodology and Key Parameters
  • 10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
    • 10.2.1. Analysis by Type of Patent
    • 10.2.2. Analysis by Patent Publication Year
    • 10.2.3. Analysis by Patent Jurisdiction
      • 10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
      • 10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
      • 10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
    • 10.2.4. Analysis by CPC Symbols
    • 10.2.5. World Cloud Analysis: Emerging Focus Areas
    • 10.2.6. Analysis by Patent Age
    • 10.2.7. Leading Industry Players: Analysis by Number of Patents
    • 10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
  • 10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
  • 10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Partnership Models
  • 11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
    • 11.2.1. Analysis by Year of Partnership
    • 11.2.2. Analysis by Type of Partnership
    • 11.2.3. Analysis by Year and Type of Partnership
    • 11.2.4. Analysis by Year and Type of Molecule
    • 11.2.5. Analysis by Focus of Partnership
    • 11.2.6. Analysis by Purpose of Partnership
    • 11.2.7. Analysis by Therapeutic Area
    • 11.2.8. Most Active Players: Analysis by Number of Partnerships
    • 11.2.9. Analysis by Geography
      • 11.2.9.1. Local and International Agreements
      • 11.2.9.2. Intracontinental and Intercontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Types of Funding
  • 12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
  • 12.3. Analysis by Year of Funding
  • 12.4. Analysis by Type of Funding
  • 12.5. Analysis by Type of Molecule
  • 12.6. Analysis of Amount Invested by Year of Funding
  • 12.7. Analysis of Amount Invested by Type of Funding
  • 12.8. Analysis by Geography
  • 12.9. Analysis by Year and Type of Funding
  • 12.10. Analysis by Purpose of Funding
  • 12.11. Analysis by Stage of Development
  • 12.12. Analysis by Therapeutic Area
  • 12.13. Most Active Players: Analysis by Number of Funding Instances
  • 12.14. Most Active Players: Analysis by Amount Invested
  • 12.15. Leading Investors: Analysis by Number of Funding Instances

13. BIG PHARMA INITIATIVES

  • 13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
    • 13.1.1. Analysis by Number of Initiatives
    • 13.1.2. Analysis by Year of Initiative
    • 13.1.3. Analysis by Type of Initiative
      • 13.1.3.1. Analysis by Type of Partnership
      • 13.1.3.2. Analysis by Type of Funding
    • 13.1.4. Analysis by Purpose of Initiative
    • 13.1.5. Analysis by Year and Number of Initiatives
    • 13.1.6. Analysis by Focus of Initiative
    • 13.1.7. Analysis by Location of Headquarters of Big Pharma Players

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035

  • 14.1. Key Assumptions and Methodology
  • 14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
    • 14.2.1. Scenario Analysis
  • 14.3. Key Market Segmentations
  • 14.4. Dynamic Dashboard

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

  • 15.1. Therapeutics: Forecasted Estimates (2023-2035)
  • 15.2. Vaccines: Forecasted Estimates (2023-2035)
  • 15.3. Data Triangulation and Validation

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

  • 16.1. repRNA: Forecasted Estimates (2023-2035)
  • 16.2. saRNA: Forecasted Estimates (2023-2035)
  • 16.3. sacRNA: Forecasted Estimates (2023-2035)
  • 16.4. sa-mRNA: Forecasted Estimates (2023-2035)
  • 16.5. tRNA: Forecasted Estimates (2023-2035)
  • 16.6. Data Triangulation and Validation

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

  • 17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
  • 17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
  • 17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
  • 17.4. Data Triangulation and Validation

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.4. Data Triangulation and Validation

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 19.1. North America: Forecasted Estimates (2023-2035)
    • 19.1.1. US: Forecasted Estimates (2023-2035)
  • 19.2. Europe: Forecasted Estimates (2023-2035)
    • 19.2.1. France: Forecasted Estimates (2023-2035)
    • 19.2.2. Italy: Forecasted Estimates (2023-2035)
    • 19.2.3. Spain: Forecasted Estimates (2023-2035)
    • 19.2.4. UK: Forecasted Estimates (2023-2035)
    • 19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
  • 19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
    • 19.3.1. India: Forecasted Estimates (2023-2035)
    • 19.3.2. Japan: Forecasted Estimates (2023-2035)
    • 19.3.3. Singapore: Forecasted Estimates (2023-2035)
  • 19.4. Data Triangulation and Validation

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

  • 20.1. Company A
  • 20.2. Company B
  • 20.3. Company C
  • 20.4. Company D
  • 20.5. Company E

21. CONCLUSION

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 6.1 List of Next Generation RNA Therapeutics and RNA Vaccines
  • Table 6.2 List of Clinical Stage Next Generation RNA Therapeutics and RNA Vaccines
  • Table 6.3 List of Next Generation RNA Therapeutic and RNA Vaccine Developers
  • Table 7.1 List of Next Generation RNA Technologies
  • Table 7.2 List of Next Generation RNA Technology / Platform Developers
  • Table 8.1 Gemcovac®: Developer Overview
  • Table 8.2 Gemcovac®: Drug Overview
  • Table 8.3 Gemcovac®: Clinical Trial Information
  • Table 8.4 Gemcovac®: Clinical Trial Endpoints
  • Table 8.5 Gemcovac®: Clinical Trial Results
  • Table 8.6 ATYR1923: Developer Overview
  • Table 8.7 ATYR1923: Drug Overview
  • Table 8.8 ATYR1923: Clinical Trial Information
  • Table 8.9 ATYR1923: Clinical Trial Endpoints
  • Table 8.10 ATYR1923: Clinical Trial Results
  • Table 8.11 ARCT-154: Developer Overview
  • Table 8.12 ARCT-154: Drug Overview
  • Table 8.13 ARCT-154: Clinical Trial Information
  • Table 8.14 ARCT-154: Clinical Trial Endpoints
  • Table 8.15 ARCT-154: Clinical Trial Results
  • Table 8.16 GRT-C901: Developer Overview
  • Table 8.17 GRT-C901: Drug Overview
  • Table 8.18 GRT-C901: Clinical Trial Information
  • Table 8.19 GRT-C901: Clinical Trial Endpoints
  • Table 8.20 GRT-C901: Clinical Trial Results
  • Table 8.21 VLPCOV-01: Developer Overview
  • Table 8.22 VLPCOV-01: Drug Overview
  • Table 8.23 AVX-901: Developer Overview
  • Table 8.24 AVX-901: Drug Overview
  • Table 8.25 AVX-901: Clinical Trial Information
  • Table 8.26 AVX-901: Clinical Trial Endpoints
  • Table 8.27 AVX-901: Clinical Trial Results
  • Table 8.28 MTL-CEBPA + Sorafenib: Developer Overview
  • Table 8.29 MTL-CEBPA + Sorafenib: Drug Overview
  • Table 8.30 MTL-CEBPA + Sorafenib: Clinical Trial Information
  • Table 8.31 MTL-CEBPA + Sorafenib: Clinical Trial Endpoints
  • Table 8.32 MTL-CEBPA + Sorafenib: Clinical Trial Results
  • Table 8.33 SLATE: Developer Overview
  • Table 8.34 SLATE: Drug Overview
  • Table 8.35 SLATE: Clinical Trial Information
  • Table 8.36 SLATE: Clinical Trial Endpoints
  • Table 8.37 SLATE: Clinical Trial Results
  • Table 9.1 RNA Therapeutics and RNA Vaccines: List of Clinical Trials, Pre-2019-2023
  • Table 10.1 RNA Therapeutics and RNA Vaccines: List of Filed / Granted Patents, 2019-2023
  • Table 11.1 RNA Therapeutics and RNA Vaccines: List of Partnerships and Collaborations, 2019-2023
  • Table 12.1 RNA Therapeutics and RNA Vaccines: List of Funding and Investments, 2019-2023
  • Table 13.1 RNA Therapeutics and RNA Vaccines: List of Big Pharma Initiatives, 2019-2023
  • Table 14.1 RNA Therapeutics and RNA Vaccines Market: Expected Launch Year of Forecasted Drug Candidates
  • Table 22.1 Next Generation RNA Therapies: Distribution by Type of Modality
  • Table 22.2 Next Generation RNA Therapies: Distribution by Type of Molecule
  • Table 22.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
  • Table 22.4 Next Generation RNA Therapies: Distribution by Phase of Development
  • Table 22.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
  • Table 22.6 Most Active Players: Distribution by Number of Therapies
  • Table 22.7 Clinical Stage Therapies: Distribution by Phase of Development
  • Table 22.8 Clinical Stage Therapies: Distribution by Route of Administration
  • Table 22.9 Clinical Stage Therapies: Distribution by Therapeutic Area
  • Table 22.10 Therapy Developer Landscape: Distribution by Year of Establishment
  • Table 22.11 Therapy Developer Landscape: Distribution by Company Size
  • Table 22.12 Therapy Developer Landscape: Distribution by Location of Headquarters
  • Table 22.13 circRNA Therapies: Distribution by Phase of Development
  • Table 22.14 circRNA Therapies: Distribution by Therapeutic Area
  • Table 22.15 Most Active Players: Distribution by Number of circRNA Therapies
  • Table 22.16 saRNA Therapies: Distribution by Phase of Development
  • Table 22.17 saRNA Therapies: Distribution by Therapeutic Area
  • Table 22.18 Most Active Players: Distribution by Number of saRNA Therapies
  • Table 22.19 Next Generation RNA Technologies: Distribution by Class of Molecule
  • Table 22.20 Next Generation RNA Technologies: Distribution by Type of Molecule
  • Table 22.21 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
  • Table 22.22 Next Generation RNA Technologies: Distribution by Therapeutic Area
  • Table 22.23 Next Generation RNA Technologies: Distribution by Highest Phase of Development
  • Table 22.24 Technology Developer Landscape: Distribution by Year of Establishment
  • Table 22.25 Technology Developer Landscape: Distribution by Company Size
  • Table 22.26 Technology Developer Landscape: Distribution by Location of Headquarters
  • Table 22.27 Technology Developer Landscape: Distribution by Operational Model
  • Table 22.28 Gemcovac®: Estimated Sales
  • Table 22.29 ATYR1923: Estimated Sales
  • Table 22.30 ARCT-154: Estimated Sales
  • Table 22.31 GRT-C901: Estimated Sales
  • Table 22.32 VLPCOV-01: Estimated Sales
  • Table 22.33 AVX901: Estimated Sales
  • Table 22.34 MTL-CEBPA + Sorafenib: Estimated Sales
  • Table 22.35 SLATE: Estimated Sales
  • Table 22.36 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
  • Table 22.37 Clinical Trial Analysis: Distribution by Trial Status
  • Table 22.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
  • Table 22.39 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 22.40 Clinical Trial Analysis: Distribution by Patients Enrolled
  • Table 22.41 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 22.42 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 22.43 Clinical Trial Analysis: Distribution by Study Design
  • Table 22.44 Leading Organizations: Distribution by Number of Trials
  • Table 22.45 Clinical Trial Analysis: Distribution by Focus Area
  • Table 22.46 Clinical Trial Analysis: Distribution by Geography
  • Table 22.47 Patent Analysis: Distribution by Type of Patent
  • Table 22.48 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
  • Table 22.49 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 22.50 Patent Jurisdiction: North American Scenario
  • Table 22.51 Patent Jurisdiction: European Scenario
  • Table 22.52 Patent Jurisdiction: Aisa-Pacific Scenario
  • Table 22.53 Patent Analysis: Distribution by Patent Age
  • Table 22.54 Patent Analysis: Distribution by CPC Symbols
  • Table 22.55 Leading Industry Players: Distribution by Number of Patents
  • Table 22.56 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 22.57 Patent Analysis: Distribution by Patent Characteristics
  • Table 22.58 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
  • Table 22.59 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Table 22.60 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 22.61 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
  • Table 22.62 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
  • Table 22.63 Partnerships and Collaborations: Distribution by Focus of Partnership
  • Table 22.64 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Table 22.65 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 22.66 Most Active Players: Distribution by Number of Partnerships
  • Table 22.67 Partnerships and Collaborations: Local and International Deals
  • Table 22.68 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 22.69 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
  • Table 22.70 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 22.71 Funding and Investment Analysis: Distribution by Type of Molecule
  • Table 22.72 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
  • Table 22.73 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 22.74 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
  • Table 22.75 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
  • Table 22.76 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Table 22.77 Funding and Investment Analysis: Distribution by Stage of Development
  • Table 22.78 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Table 22.79 Most Active Players: Distribution by Number of Funding Instances
  • Table 22.80 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 22.81 Leading Investors: Distribution by Number of Funding Instances
  • Table 22.82 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Table 22.83 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2019-2023
  • Table 22.84 Big Pharma Initiatives: Distribution by Type of Initiative
  • Table 22.85 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
  • Table 22.86 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
  • Table 22.87 Big Pharma Initiatives: Distribution by Focus of Initiative
  • Table 22.88 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
  • Table 22.89 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
  • Table 22.90 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
  • Table 22.91 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
  • Table 22.92 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
  • Table 22.93 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.94 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.95 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
  • Table 22.96 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.97 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.98 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.99 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.100 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.101 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
  • Table 22.102 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.103 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.104 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.105 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
  • Table 22.106 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.107 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.108 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.109 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
  • Table 22.110 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.111 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.112 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.113 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.114 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.115 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.116 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.117 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.118 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.119 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.120 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.121 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.122 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)

List of Figures

  • Figure 4.1 Executive Summary: Overall Market Landscape
  • Figure 4.2 Executive Summary: Overall Technology Landscape
  • Figure 4.3 Executive Summary: Clinical Trial Analysis
  • Figure 4.4 Executive Summary: Patent Analysis
  • Figure 4.5 Executive Summary: Partnerships and Collaborations
  • Figure 4.6 Executive Summary: Funding and Investment Analysis
  • Figure 4.7 Executive Summary: Big Pharma Initiatives
  • Figure 4.8 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
  • Figure 5.2 Key Aspects of Next Generation RNA Molecules
  • Figure 5.3 Key Challenges Associated with Traditional RNA Modalities
  • Figure 5.4 Advantages of Using Next Generation RNA Modalities
  • Figure 6.1 Next Generation RNA Therapies: Distribution by Type of Modality
  • Figure 6.2 Next Generation RNA Therapies: Distribution by Type of Molecule
  • Figure 6.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
  • Figure 6.4 Next Generation RNA Therapies: Distribution by Phase of Development
  • Figure 6.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
  • Figure 6.6 Most Active Players: Distribution by Number of Therapies
  • Figure 6.7 Clinical Stage Therapies: Distribution by Phase of Development
  • Figure 6.8 Clinical Stage Therapies: Distribution by Route of Administration
  • Figure 6.9 Clinical Stage Therapies: Distribution by Therapeutic Area
  • Figure 6.10 Therapy Developer Landscape: Distribution by Year of Establishment
  • Figure 6.11 Therapy Developer Landscape: Distribution by Company Size
  • Figure 6.12 Therapy Developer Landscape: Distribution by Location of Headquarters
  • Figure 6.13 circRNA Therapies: Distribution by Phase of Development
  • Figure 6.14 circRNA Therapies: Distribution by Therapeutic Area
  • Figure 6.15 Most Active Players: Distribution by Number of circRNA Therapies
  • Figure 6.16 saRNA Therapies: Distribution by Phase of Development
  • Figure 6.17 saRNA Therapies: Distribution by Therapeutic Area
  • Figure 6.18 Most Active Players: Distribution by Number of saRNA Therapies
  • Figure 7.1 Next Generation RNA Technologies: Distribution by Class of Molecule
  • Figure 7.2 Next Generation RNA Technologies: Distribution by Type of Molecule
  • Figure 7.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
  • Figure 7.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
  • Figure 7.5 Next Generation RNA Technologies: Distribution by Highest Phase of Development
  • Figure 7.6 Technology Developer Landscape: Distribution by Year of Establishment
  • Figure 7.7 Technology Developer Landscape: Distribution by Company Size
  • Figure 7.8 Technology Developer Landscape: Distribution by Location of Headquarters
  • Figure 7.9 Technology Developer Landscape: Distribution by Operational Model
  • Figure 8.1 Gemcovac®: Estimated Sales
  • Figure 8.2 ATYR1923: Estimated Sales
  • Figure 8.3 ARCT-154: Estimated Sales
  • Figure 8.4 GRT-C901: Estimated Sales
  • Figure 8.5 VLPCOV-01: Estimated Sales
  • Figure 8.6 AVX901: Estimated Sales
  • Figure 8.7 MTL-CEBPA + Sorafenib: Estimated Sales
  • Figure 8.8 SLATE: Estimated Sales
  • Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
  • Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
  • Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 9.5 Clinical Trial Analysis: Distribution by Patients Enrolled
  • Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 9.7 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.9 Leading Organizations: Distribution by Number of Trials
  • Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
  • Figure 9.11 Clinical Trial Analysis: Distribution by Geography
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
  • Figure 10.3 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 10.4 Patent Jurisdiction: North American Scenario
  • Figure 10.5 Patent Jurisdiction: European Scenario
  • Figure 10.6 Patent Jurisdiction: Aisa-Pacific Scenario
  • Figure 10.7 Patent Analysis: Distribution by Patent Age
  • Figure 10.8 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.9 Word Cloud Analysis: Emerging Focus Areas
  • Figure 10.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.12 Patent Analysis: Distribution by Patent Characteristics
  • Figure 10.13 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
  • Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
  • Figure 11.4 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
  • Figure 11.5 Partnerships and Collaborations: Distribution by Focus of Partnership
  • Figure 11.6 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 11.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.9 Partnerships and Collaborations: Local and International Deals
  • Figure 11.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
  • Figure 12.2 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 12.3 Funding and Investment Analysis: Distribution by Type of Molecule
  • Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
  • Figure 12.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 12.6 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million
  • Figure 12.7 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
  • Figure 12.8 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Figure 12.9 Funding and Investment Analysis: Distribution by Stage of Development
  • Figure 12.10 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Figure 12.11 Most Active Players: Distribution by Number of Funding Instances
  • Figure 12.12 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 12.13 Leading Investors: Distribution by Number of Funding Instances
  • Figure 13.1 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Figure 13.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
  • Figure 13.3 Big Pharma Initiatives: Distribution by Type of Initiative
  • Figure 13.4 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
  • Figure 13.5 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
  • Figure 13.6 Big Pharma Initiatives: Distribution by Focus of Initiative
  • Figure 13.7 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
  • Figure 14.1 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
  • Figure 14.2 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
  • Figure 14.3 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
  • Figure 15.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
  • Figure 15.2 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 15.3 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
  • Figure 16.2 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.3 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.4 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.5 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.6 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
  • Figure 17.2 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.3 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.4 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
  • Figure 18.2 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.3 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.4 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
  • Figure 19.2 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.3 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.4 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.5 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.6 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.7 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.8 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.9 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.10 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.11 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.12 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.13 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 20.1 RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)